A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Eszopiclone (Lunesta)

Non-Benzodiazepine Hypnotic (Z-Drug) class · 10 generic manufacturers · 30 ANDAs filed at FDA.

First FDA approval2013-03-26
Generic availableYes · 10 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$35.6M in CY2024 Part D spend1.3M claims · 352K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.085/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.088
Across all dosage forms in distribution.
Highest NADAC
$0.097
Range is tight.
Plans with PA
112 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Eszopiclone used for?

Eszopiclone is a Non-Benzodiazepine Hypnotic (Z-Drug) medication tracked in Medicare Part D.

Is there a generic for Eszopiclone?

Yes. 30 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Eszopiclone?

Across 329 Part D plans, Eszopiclone averages $0.088/unit (NADAC). Lowest available: $0.085/unit. Highest in distribution: $0.097/unit.

Is Eszopiclone on the FDA shortage list?

Eszopiclone has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Non-Benzodiazepine Hypnotic (Z-Drug)1 alternative in D1
01
Zolpidem
Brand: Ambien
$0.035Lowest NADAC
12Generic mfrs
$120.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.